Research programme: antibacterial therapeutics - Gunsynd

Drug Profile

Research programme: antibacterial therapeutics - Gunsynd

Alternative Names: SYN 0017; SYN 0096; SYN 0854; SYN 101; SYN 102; SYN 1093; SYN 1163

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Syntopix
  • Developer Gunsynd
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acne; Staphylococcal infections

Highest Development Phases

  • Preclinical Acne; Mouth disorders; Staphylococcal infections

Most Recent Events

  • 25 Oct 2011 Syntopix is now called Evocutis
  • 23 Feb 2011 At least two compounds (SYN0126 and SYN1113) that will have come from this trial have been found to be being developed for cosmetics and soaps - not pharmaceuticals. This casts doubt on the RP - but until it is clear nothing can be done.
  • 22 Feb 2011 Preclinical development for Acne, Staphylococcal infections and Mouth Disorders is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top